Enzymes involved in collagen biosynthesis, including lysyl oxidase (LOX), have been proposed as potential therapeutic targets for idiopathic pulmonary fibrosis. LOX expression is significantly upregulated in belomycin (BLM)-induced lung fibrosis, and knockdown of LOX expression or inhibition of LOX activity alleviates the lung fibrosis. Unexpectedly, treatment of the mice with LOX inhibitor at the inflammatory stage, but not the fibrogenic stage, efficiently reduces collagen deposition and normalizes lung architecture. Inhibition of LOX impairs inflammatory cell infiltration, TGF- signaling, and myofibroblast accumulation. Furthermore, ectopic expression of LOX sensitizes the fibrosis-resistant Balb/c mice to BLM-induced inflammation and lung fibrosis. These results suggest that LOX is indispensible for the progression of BLM-induced experimental lung fibrosis by aggravating the inflammatory response and subsequent fibrosis process after lung injury.
Introduction
Lung fibrosis, characterized by replacement of normal tissue with scar tissue, destruction of tissue architecture, and organ malfunction, is a progressive chronic interstitial lung disease with poor outcome (King et al., 2011; Wynn, 2011; Noble et al., 2012) . Lung fibrosis can develop after exposure to radiotherapy, chemotherapy, or environmental toxins (Wynn, 2011) . After injury of pulmonary epithelial and endothelial cells, the damaged tissues are repaired by precisely coordinated inflammatory cell infiltration, fibroblast/myofibroblast proliferation, migration, and activation, epithelial cell proliferation and migration, as well as extracellular matrix (ECM) remodeling (Schafer and Werner, 2008; Araya and Nishimura, 2010; King et al., 2011; Wynn, 2011) . Dysregulation of such wound healing process leads to the development of permanent fibrotic scar with excess accumulation of ECM components at the site of injury (Schafer and Werner, 2008; Araya and Nishimura, 2010; King et al., 2011; Wynn, 2011) . Although debate exists whether inflammation is required for the progression of lung fibrosis, it is believed that the fibrosis is at least initially induced by inflammatory response after epithelial and endothelial cell injury (Lopez-Novoa and Nieto, 2009; Araya and Nishimura, 2010; du Bois, 2010; Wynn, 2011; Noble et al., 2012) .
As the endpoint of lung fibrosis, excess deposition of ECM components and replacement of cellular tissue with acellular ECM severely compromise tissue structure and function. Therefore, the fibrosis process should be controllable by suppressing the production and deposition of ECM components, especially the interstitial collagens (Kagan, 2000) . Interstitial collagen precursors undergo a serial post-translational enzymatic modifications before their deposition into ECM, including proline hydroxylation catalyzed by prolyl 4-hydroxylase (PHD) (Gorres and Raines, 2010) , proteolytical removal of N-and C-propeptides catalyzed by procollagen N-proteinases (PNPs) ADAMTS-2, 3, and 14 and procollagen C-proteinases (PCPs) bone morphogenetic protein-1 (BMP-1)/tolloid (TLD) family metalloproteinases (Greenspan, 2005; Ge and Greenspan, 2006) , and collagen oxidation and crosslinking catalyzed by copper-dependent lysyl oxidase (LOX) family oxidases (Lucero and Kagan, 2006; Xiao and Ge, 2012) . The primary function of LOX family oxidases is to oxidize amine substrates to reactive aldehydes, which results in the crosslinking of collagen and elastin (Lucero and Kagan, 2006; Xiao and Ge, 2012) . LOX expression is markedly elevated in lung fibrosis, liver cirrhosis, atherosclerosis, scleroderma, and desmoplastic tumors featured by prominent symptom of fibrosis (Murawaki et al., 1991; Chanoki et al., 1995; Kagan, 2000) . LOX blocking antibody treatment prevented bleomycin (BLM)-or irradiation-induced lung fibrosis (Cox et al., 2013) . LOXL2 blocking antibody treatment also successfully impeded BLM-induced lung fibrosis (Barry-Hamilton et al., 2010) . However, it requires further investigation to determine whether LOX indeed impact the progression of these fibrotic diseases by facilitating collagen crosslinking and deposition or other mechanisms.
In this report, we provide evidence supporting that LOX is the most significantly upregulated collagen post-translational modifying enzyme in BLM-induced experimental lung fibrosis and inhibition of LOX activity alleviates the fibrosis progression. Unexpectedly, blocking LOX activity at the fibrogenic stage can not efficiently prevent further progression of lung fibrosis, while inhibition of LOX activity at the inflammatory stage impaired inflammatory cell infiltration, TGF- signaling, and lung fibrosis. Ectopic LOX expression enhances the inflammatory response and sensitizes the fibrosis-resistant Balb/c mice to BLM-induced lung fibrosis, corroborating that LOX promotes lung fibrosis mainly through modulating inflammation.
Results

Elevated LOX expression during BLM-induced lung fibrosis
After BLM challenge, C57BL/6 mice displayed collapse of the alveolar spaces and extensive collagen production and deposition in the lung (Supplementary Figure S1A and B). mRNA levels of the enzymes involved in collagen biosynthesis, including PHD, PNPs, PCPs, and LOX family oxidases, in lung tissues after 14 days were determined. BLM substantially induced the expression of LOX, LOXL2, prolyl 4-hydroxylase subunit 2 (P4HA2), and ADAMTS2, among which, LOX was most significantly upregulated (~8-fold) (Supplementary Figure S1) . Further analyses showed that Lox mRNA level steadily increased from Day 3 to 21 ( Figure 1A ), compared with Loxl2 expression that was only evident on Day 14 and 21 (Supplementary Figure   S2A ). LOX protein level increased on Day 7 (~4-fold) and 14 (~9.5-fold) ( Figure 1B ) and the protein was broadly expressed in the alveolar and bronchiolar epithelium and fibroblasts (Supplementary Figure S2B and C), whereas LOXL2 is predominantly expressed in myofibroblasts (Supplementary Figure S2B) .
LOX is indispensible for BLM-induced lung fibrosis
To investigate the role of LOX expression in BLM-induced experimental lung fibrosis, the LOX knockdown experiment was performed on C57BL/6 mice by administration of Figure S3) and Ad-shLox successfully reduced Lox mRNA ( Figure 1D ) and LOX protein levels ( Figure 1E ) in mouse lungs harvested on Day 14. Mice received Ad-shLox showed significantly less body weight loss after BLM challenge than those received Ad-shCtrl ( Figure 1F ). Histological analysis revealed BLM-induced tissue architecture destruction and dense collagen deposition in lungs from Ad-shCtrl-treated mice, which were markedly reduced in Ad-shLox-treated mice ( Figure 1G ). The extent of fibrosis, determined as Ashcroft score, was significantly decreased in both Ad-shLox groups ( Figure 1H ).
The collagen content, determined by measuring hydroxyproline level in the lungs, was significantly lower in Ad-shLox groups ( Figure 1I ). Concurrently, mRNA levels of collagens and fibronectin were lower in Ad-shLox-treated mouse lungs ( Figure 1J ).
Since LOX oxidase activity is critical in mediating the crosslinking and deposition of collagens, we further study whether LOX enzymatic activity also impacts BLM-induced lung fibrosis. The inhibition experiment was performed on C57BL/6 mice by daily administration of the LOX inhibitor -aminoproprionitrile (BAPN) or saline as control from one day before BLM challenge (Day -1) till the end of the experiment (Figure 2A ). BAPN treatment (Day -1 to 21) resulted in significantly less body weight loss ( Figure 2B ), reduced tissue destruction and collagen deposition ( Figure 2C ), as well as decreased Ashcroft score ( Figure 2D ), hydroxyproline content ( Figure 2E ), and mRNA levels of ECM proteins ( Figure 2F ). Thus, LOX oxidase activity is important in the progression of BLM-induced lung fibrosis. 
Ectopic LOX sensitizes Balb/c mice to BLM-induced lung fibrosis
Unlike C57BL/6 mice, Balb/c mice are relatively resistant to BLM-induced lung fibrosis (Hoyt and Lazo, 1988; Kolb et al., 2002; Warshamana et al., 2002) . In the lungs of Balb/c mice subjected to BLM challenge, only sparse collagen-rich foci were evident (Supplementary Figure   S4A ), the expression of collagens and fibronectin was mildly upregulated (Supplementary Figure   S4B ), and notably, LOX expression remained largely unchanged (Supplementary Figure S4C) .
Next, the ectopic LOX expression experiment was performed on Balb/c mice by administration of adenoviruses harboring LOX or its mutant at 3 days before BLM challenge ( Figure 3A and B).
K320A/Y355F mutations disrupt the lysyl tyrosyl quinine cofactor and the oxidase activity of LOX (Kagan and Li, 2003; Gao et al., 2010; Baker et al., 2011) . Mice received Ad-LOX, but not Ad-GFP nor Ad-LOX mut that expresses enzymatically inactive LOX, substantially developed lung fibrosis after BLM challenge, accompanied with body weight loss ( Figure 3C 
LOX is required for TGF- signaling and myofibroblast accumulation
Myofibroblasts are key cellular effectors responsible for ECM production and remodeling during BLM-induced lung fibrosis (Lopez-Novoa and Nieto, 2009; Araya and Nishimura, 2010) . 
Inhibition of LOX activity at the fibrogenic stage does not efficiently alleviate lung fibrosis progression
The BLM model of lung fibrosis has been characterized by an initial influx of inflammatory cells during the inflammatory stage in response to BLM-induced tissue injury, followed by fibrotic reactions during the fibrogenic stage (Shen et al., 1988) . Accordingly, interventions during the first 7 days are considered for preventive purpose, while treatments during later stages, i.e. after 7 days, are considered for therapeutic purpose (Moeller et al., 2008) . As LOX family oxidases play critical roles in collagen crosslinking and connective tissue homeostasis, we next investigated whether LOX could serve as a therapeutic target. LOX activity was inhibited by daily administration of BAPN from Day 7 to 21 after BLM challenge ( Figure 5A ). This treatment alleviated BLM-induced body weight loss ( Figure 5B Figure 7F ). These findings suggest that LOX may promote lung fibrosis by modulating inflammatory cell infiltration, a mechanism independent of interstitial collagen crosslinking and deposition.
Inhibition of LOX activity at the inflammatory stage prevented lung fibrosis
The elevated LOX expression at the inflammatory stage ( Figures 1A and B and 7A) promoted us to investigate whether LOX inhibition at the inflammatory stage affected BLM-induced lung fibrosis. C57BL/6 mice received daily administration of BAPN only for the first 7 days after BLM challenge ( Figure 8A ), which suppressed BLM-induced widespread cell apoptosis in the lung to the baseline ( Figure 8B and Supplementary Figure S7 ). This BAPN treatment substantially reduced the inflammatory cell number ( Figure 8C ) and resulted in similar protective effects against BLM-induced lung fibrosis, as observed from administration of Lox shRNAs or long-period BAPN treatment (Day -1 to 21), which were featured by less body weight loss ( Figure 8D ), less severe tissue destruction ( Figure 8E ), reduced collagen deposition and extent of fibrosis ( Figure 8E−G) , decreased mRNA levels of ECM proteins ( Figure 8H ), and impaired TGF- signaling and myofibroblast accumulation ( Figure 8I−N) . Thus, LOX inhibition at the inflammatory stage sufficiently impaired inflammatory cell infiltration and prevented the development of BLM-induced lung fibrosis.
Discussion
Aberrant expression and activity of LOX, the key enzyme mediating collagen crosslinking, have been believed to contribute to the pathological progression of lung fibrosis (Counts et al., 1981; Decitre et al., 1998; Barry-Hamilton et al., 2010; Cox et al., 2013) . It has also been proposed that the fibrosis process in principal should be controllable by inhibiting LOX and suppressing the production and deposition of interstitial collagens (Kagan, 2000) . In this study, we present evidence that LOX functions more prominently in the initial inflammatory phase rather than later fibrogenic stages, in contrast to the current scenario that LOX plays more crucial roles at the fibrogenic stage, when the collagen production, maturation, and deposition occur.
LOX mainly affects the number of macrophages in BLM-induced lung fibrosis (Figure 7 ). LOX and LOXL2 secreted by primary tumors are reported to accumulate at the premetastatic sites, crosslink basement membrane type IV collagen, and recruit CD11b + myeloid cells to form the premetastatic niche, while LOX inhibition prevents CD11b + cell recruitment and metastatic tumor growth (Erler et al., 2009; Park et al., 2011; Wong et al., 2011) . Macrophages are multifunctional in the tissue repair and fibrosis process by promoting inflammation, angiogenesis, fibroblast proliferation, myofibroblast recruitment, and ECM synthesis (Koh and DiPietro, 2011) .
Depletion of macrophages in mice results in delayed wound closure and lung fibrosis (Duffield et al., 2005; Murray et al., 2011) . Macrophage is also the major source of TGF-, the key cytokine in the development of lung fibrosis (Khalil et al., 1993) . As a result of decreased macrophage infiltration, blocking LOX activity attenuated TGF- signaling in C57BL/6 mice, whereas ectopic LOX expression enhanced the TGF- signaling in Balb/c mice ( Figure 4 ). Consistently, LOX inhibitor treatment at the fibrogenic stage (Day 10 to 21), which did not reduce the number of infiltrating macrophages, had no obvious effect on the progression of lung fibrosis ( Figure 6 ). Figure S2) . Myeloid cell-derived TGF- induces LOX expression in resident tissue fibroblasts that subsequently promotes breast cancer metastasis (Pickup et al., 2013) . antibody satisfactorily inhibited lung fibrosis, liver fibrosis, breast cancer growth and metastasis (Barry-Hamilton et al., 2010) . It is controversial whether LOX inhibitor BAPN indeed inhibits LOXL2 enzymatic activity (Vadasz et al., 2005; Rodriguez et al., 2010) . In addition to collagens and elastin, LOX readily oxidizes basic globular proteins, e.g. histone H1 (Kagan et al., 1983) , and non-peptidyl amine substrates, e.g. 1,5-diaminopentane (Palamakumbura and Trackman, 2002) in vitro. BAPN potently inhibits the oxidase activity of both LOX and LOXL2 when 1,5-diaminopentane was used as the substrate (Palamakumbura and Trackman, 2002; Erler et al., 2006; Barry-Hamilton et al., 2010; Rodriguez et al., 2010) . However, BAPN at the concentration (0.05 mg/ml, 0.7 mM) that completely inhibits LOX activity can not efficiently inhibit the oxidizing activity of LOXL2 when physiological substrate collagen is used in an in vitro assay (Vadasz et al., 2005) . Indeed, LOXL2 blocking antibody, but not BAPN, resulted in significant reduction in tumor growth, accompanied with reduced collagen crosslinking, fibroblast activation, and endothelial cell recruitment in the tumor microenvironment (Barry-Hamilton et al., 2010) . It is conceivable that LOXL2, but not LOX, plays more crucial roles in promoting collagen crosslinking and deposition at the fibrogenic stage. It is also possible that BAPN is not potent enough to completely inhibit the activity of high level of LOX and LOXL2 at the fibrogenic stage.
Abundant LOX and LOXL2 expression has been observed in the myofibroblasts (Supplementary
In summary, LOX expression is markedly elevated in BLM-induced lung fibrosis. In contrast to its presumed functions in collagen deposition at the fibrogenic stage, this study provides evidence supporting that LOX primarily functions as a critical regulator in the inflammatory response after tissue injury.
Materials and methods
BLM-induced lung fibrosis
All mice were housed in a specific pathogen-free environment at the Shanghai Institute of 
Adenoviruses
Human LOX and GFP were cloned into pShuttle-CMV vector. shRNA sequences were cloned into pLKO.1-puro retroviral vector and the shRNAs with U6 promoter were then cloned into pShuttle vector followed by recombination with pAdEasy vector (AdEasy TM Adenovirial vector system, Stratagene). shRNA target sequences are scramble control:
5′-CAAGATGAAGAGCACCAA-3′; Lox-#1: 5′-GATGGCGATATATGTATTC-3′; and Lox-#2:
5′-CCAGTGAAACAATGATGAT-3′. The adenoviruses were packaged in HEK-293 cells and purified with CsCl gradient centrifugation. At 3 days before BLM instillation, 1×10 8 pfu adenoviruses in 30 μl PBS were instilled intranasally to the mice.
BALF collection, ELISA, and differential cell counting
Lungs were lavaged with two sequential 1-ml PBS after 14 days of BLM administration.
BALF was pooled and centrifuged, and the cell pellet was washed with and resuspended in PBS.
Cells were counted with a hemocytometer and differential cell counting was performed after centrifugation in cytospin with May Grunwald/Giemsa staining using Hemacolor® (Merck).
TGF- level in BALF was measured with the ELISA kit (R&D systems).
Histology, immunohistochemistry, immunofluorescence, and Picro Sirius red staining
The left lobe of Lung was perfused, fixed with 4% paraformaldehyde in PBS, dehydrated, and embedded in paraffin. Paraffin sections (5 μm) were stained with hematoxylin and eosin A or Picro Sirius red solution. Immunohistochemical staining was performed with Histostain-Plus Kit 
Hydroxyproline quantification
Total collagen content was measured with a conventional hydroxyproline quantitation method (Huszar et al., 1980) .
Quantitative RT−PCR analysis
Quantitative RT−PCR was performed as previously described (Gao et al., 2010) to determine mRNA levels of Lox and other genes. The primers used are listed in Supplementary Table S1 . 
Western blot analysis
Western blot analysis was performed as previously described (Gao et al., 2010) to determine protein levels of LOX and β-actin as loading control.
Statistical analysis
Data are presented as means ± SD and analyzed by Student's two-tailed t test. P < 0.05 is considered statistically significant. Balb/c mice in the ectopic LOX expression experiment (B, procedure in Figure 3A ), C57BL/6
